Netherlands Cancer Institute
TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma?
Premium
Based on data from a randomized trial presented at ESMO, the Netherlands Cancer Institute is exploring the possibility of seeking regulatory approval for TIL therapy without pharma involvement.
Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor
Researchers at ASCO shared data pointing to gene amplification, protein overexpression, and TP53 mutations as biomarkers for identifying best responders to adavosertib.
Early ESMO Data Show Interferon Signature's Ability to Guide Neoadjuvant Melanoma Immunotherapy
In the Phase I DOMINI trial, patients received combinations of BMS' Opdivo, Yervoy, and 4SC's domatinostat based on their tumors' interferon gamma gene expression.
Single Metastatic Cancer Genome Analysis Appears Sufficient to ID Biomarkers, Treatment Options
For many metastatic cancer patients, actionable genomic alterations uncovered in the initial analysis did not change much in later biopsies.
Based on results from a pilot study, Dutch lawmakers are advancing a proposal to make WGS a standard test for advanced cancer patients.